melanoma

FDA-approved TIL therapy lifileucel shows durable responses in metastatic melanoma—and next-generation versions are coming.

Lifileucel received FDA approval for unresectable/metastatic melanoma after PD-1/PD-L1 failure. The C-144-01 study showed median duration of response 36.5 months, median OS 13.9 months, 5-year OS rate 19.7%. However, current TIL therapy requires intensive lymphodepletion and high-dose IL-2, limiting adoption. Next-generation platforms aim to improve persistence and reduce toxicity: OBX-115 (membrane-bound IL-15), KSQ-001EX/004EX (CRISPR-enhanced), and other engineered approaches.

Key Findings

Lifileucel: median DoR 36.5 months, OS 13.9 months, 5-year OS 19.7% in anti-PD-1/PD-L1 resistant melanoma
Classical TIL requires intensive lymphodepletion and high-dose IL-2—significant toxicity barrier
OBX-115 uses regulatable IL-15 eliminating IL-2 need; showed early clinical activity
KSQ-001EX uses CRISPR to inactivate SOCS1; KSQ-004EX also targets Regnase-1
5-year OS of 19.7% is a major advance in PD-1 resistant metastatic melanoma

Implications

TIL therapy is now FDA-approved and clinically available for PD-1 resistant metastatic melanoma. Ongoing engineered TIL development aims to improve accessibility and durability while reducing toxicity.

Caveats

Review article; abstract-only. FDA approval based on single-arm study. Toxicity and logistical barriers limit broad implementation. Next-generation platforms are investigational.

Source: Frontiers in immunology — 2026-01-01

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.